Intas Pharmaceuticals Limited — Sertraline Exporter Profile
Indian Pharmaceutical Exporter · #13 for Sertraline · $2.3M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #13 Indian exporter of Sertraline with $2.3M in export value and 414 verified shipments. Intas Pharmaceuticals Limited holds a 0.9% market share in Sertraline exports across 12 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Sertraline Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Sertraline?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $755.0K | 85 | 36.6% |
| UNITED KINGDOM | $585.9K | 37 | 28.4% |
| MEXICO | $201.7K | 12 | 9.8% |
| POLAND | $170.7K | 61 | 8.3% |
| BRAZIL | $166.7K | 30 | 8.1% |
| SINGAPORE | $138.1K | 6 | 6.7% |
| GREECE | $23.0K | 37 | 1.1% |
| UNITED STATES | $9.1K | 1 | 0.4% |
| MALTA | $6.1K | 149 | 0.3% |
| MAURITIUS | $2.5K | 3 | 0.1% |
Intas Pharmaceuticals Limited exports Sertraline to 13 countries. The largest destination is NETHERLANDS accounting for 36.6% of Intas Pharmaceuticals Limited's Sertraline shipments, followed by UNITED KINGDOM (28.4%) and MEXICO (9.8%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Sertraline from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BROCACEF NL : HUB | NETHERLANDS | $378.9K | 56 |
| TO THE ORDER | MAURITIUS | $345.1K | 15 |
| ACCORD UK | UNITED KINGDOM | $309.7K | 16 |
| ACCORD FARMA S.A. DE C.V. | MEXICO | $201.7K | 12 |
| BROCACEF NL:EU HUB | NETHERLANDS | $132.6K | 10 |
| ACCORD FARMACUTICA LTDA. | BRAZIL | $132.5K | 26 |
| ACCORD HEALTHCARE PTE LTD | SINGAPORE | $79.9K | 4 |
| BROCACEF NL HUB BROCACEF HEALTHCAR | NETHERLANDS | $71.7K | 5 |
| BROCACEF NL:HUB | NETHERLANDS | $67.2K | 6 |
| BROCACEF NL HUB | NETHERLANDS | $53.6K | 3 |
Intas Pharmaceuticals Limited supplies Sertraline to 33 buyers globally. The largest buyer is BROCACEF NL : HUB (NETHERLANDS), followed by TO THE ORDER (MAURITIUS) and ACCORD UK (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Sertraline Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $150.8M worth of Sertraline through 5,183 shipments from 218 suppliers to 88 countries, serving 553 buyers globally. Intas Pharmaceuticals Limited contributes $2.3M to this total, accounting for 0.9% of India's Sertraline exports. Intas Pharmaceuticals Limited ships Sertraline to 13 countries through 33 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Sertraline Exports?
Intas Pharmaceuticals Limited's average Sertraline shipment value is $5.6K per consignment, based on 414 shipments totaling $2.3M. The largest destination is NETHERLANDS (36.6% of Intas Pharmaceuticals Limited's Sertraline exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Sertraline Exporters?
Intas Pharmaceuticals Limited ranks #13 among 218 Indian Sertraline exporters with a 0.9% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($34.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($32.1M), CIPLA LIMITED ($27.5M). Intas Pharmaceuticals Limited processed 414 shipments to 12 destination countries.
What Sertraline Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARM DRUG&MED:SERTRALIN 50MG 28000T TLB(ACO-EUROPE)EACH FILM COATED TABLET CONTSERTRALINE HYDROCHLORIDE PH.E(ASPERINV) | $190.4K | 4 |
| PHARMA DRUGS & MEDI SERTRALINE 100MG 250 | $108.2K | 7 |
| PHARMA DRUGS AND MEDICINE-ACORTRAL-50MG14 TAB(E1)EACH FILM COATED TABLET CONTAINS:SERTRALINE-QTY-136447X1X14T-AS PER INTBS | $94.6K | 3 |
| PHARMA DRUGS & MEDI SERTRALINE 100MG 10X | $82.9K | 4 |
| PHARMA DRUGS AND MEDICINE-ACORTRAL-50MG14 TAB(E1)EACH FILM COATED TABLET CONTAINS:SERTRALINE QTY-99220X1X14T-AS PER INVTBS | $69.3K | 3 |
| PHARMA DRUGS & MEDI SERTRALINE 50MG 250T | $66.1K | 9 |
| PHARM DRUG&MED:SERTRALIN 100MG 14000T TLB(ACO-EUROPE)EACH FILM COATED TABLET CONT SERTRALINE HYDROCHLORIDE PH (ASPERINV) | $65.7K | 2 |
| PH.DRU.& MED.: ACOLOFT 50MG TABLETS (SERTRALINE 50MG TABLETS EACH TABLET CONT. SERTRALINE 50MG) [2X14T PER PACK] BATCH N | $63.0K | 2 |
| PHARMA DRUGS & MEDI SERTRALINE 50MG 3X10 | $63.0K | 6 |
| PHARMA DRUGS & MEDI SERTRALINE 50MG 2X14 | $62.6K | 6 |
Intas Pharmaceuticals Limited exports 152 distinct Sertraline formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARM DRUG&MED:SERTRALIN 50MG 28000T TLB(ACO-EUROPE)EACH FIL with 4 shipments worth $190.4K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Sertraline to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Sertraline to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Sertraline Exporters?
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | MEDREICH LIMITED | $2.4M | 70 | 1 | $34.5K |
| 11 | TORRENT PHARMACEUTICALS LIMITED | $2.4M | 47 | 5 | $50.0K |
| 13 | INTAS PHARMACEUTICALS LIMITED ★ | $2.3M | 414 | 12 | $5.6K |
| 14 | ZYDUS LIFESCIENCES LIMITED | $2.0M | 95 | 9 | $20.9K |
| 15 | EMIL PHARMACEUTICAL INDUSTRIES PVT LTD | $1.8M | 53 | 3 | $34.6K |
Intas Pharmaceuticals Limited ranks #13 among 218 Indian Sertraline exporters. Average shipment value of $5.6K compared to the market average of $691.9K. The closest competitors by value are MEDREICH LIMITED and TORRENT PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Sertraline Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 592 | 11.4% |
| SAHAR AIR | 498 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 382 | 7.4% |
| DHANNAD ICD | 268 | 5.2% |
| HYDERABAD ICD | 184 | 3.6% |
| DHANNAD ICD (INDHA6) | 177 | 3.4% |
| DELHI AIR | 173 | 3.3% |
| VIZAG SEA (INVTZ1) | 172 | 3.3% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Sertraline Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Sertraline, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Sertraline — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Sertraline shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 427 individual customs records matching Intas Pharmaceuticals Limited exporting Sertraline, covering 152 formulations to 13 countries via 33 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 88+ countries, 553+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Sertraline Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Sertraline exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Sertraline Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Sertraline. For current shipment-level data, contact TransData Nexus.